- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Differential Ability Scales.
Displaying page 1 of 1.
EudraCT Number: 2018-003180-54 | Sponsor Protocol Number: 20275 | Start Date*: 2020-04-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090 | |||||||||||||
Medical condition: Retinopathy of prematurity | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) AT (Prematurely Ended) HU (Completed) ES (Trial now transitioned) NL (Prematurely Ended) PT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) LV (Completed) EE (Completed) IT (Trial now transitioned) PL (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002582-37 | Sponsor Protocol Number: CS001/2005 | Start Date*: 2006-01-13 |
Sponsor Name:Allergie-Centrum-Charité Universitätsmedizin Berlin | ||
Full Title: Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients | ||
Medical condition: Urticaria is a very frequent skin condition characterised by transient wheal and flare type skin reactions associated with severe pruritus. In Europe alone, more than 5 million patients are thought... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000924-11 | Sponsor Protocol Number: CTCL | Start Date*: 2015-06-17 | |||||||||||
Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor | |||||||||||||
Full Title: Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma. | |||||||||||||
Medical condition: Cutaneous T cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002741-38 | Sponsor Protocol Number: SymPro2012 | Start Date*: 2013-10-02 | |||||||||||
Sponsor Name:SymbioPharm GmbH | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy,safety and tolerability of oral treatment with non-pathogenic bacterial lysate of E. coli and E. faecalis c... | |||||||||||||
Medical condition: Irritable Bowel Syndrome (IBS) with recurrent abdominal pain or discomfort according to ‘S3 Guideline and Rome III criteria’ | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004143-13 | Sponsor Protocol Number: SHP-609-302 | Start Date*: 2015-03-19 | ||||||||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | ||||||||||||||||||
Full Title: An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome... | ||||||||||||||||||
Medical condition: Hunter syndrome and cognitive impairment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002885-38 | Sponsor Protocol Number: HGT-HIT-094 | Start Date*: 2013-10-22 | |||||||||||
Sponsor Name:Shire HGT Inc | |||||||||||||
Full Title: A Controlled,Randomized,Two-arm,Open-label,Assessor-blinded,Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and... | |||||||||||||
Medical condition: Long-term treatment of Hunter syndrome and cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
